Abeo Therapeutics

Abeona Therapeutics is a commercial-stage biopharmaceutical company focused on cell and gene therapies for serious diseases, particularly rare genetic disorders. Its lead commercial product is ZEVASKYN (prademagene zamikeracel), an autologous cell-based gene therapy approved in the United States for wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa. Beyond its commercial dermatology program, the company is advancing an ophthalmology pipeline of AAV-based gene therapies, including candidates for X-linked retinoschisis, Stargardt disease, and autosomal dominant optic atrophy. Abeona also highlights proprietary AIM capsid technology for next-generation AAV vector design and has partnered certain external gene therapy assets. The company operates with integrated capabilities spanning development, manufacturing, and commercialization.